This review concluded that eradication therapy in immune thrombocytopaenia purpura should be reserved for H. pylori positive patients. The authors have drawn relatively cautious conclusions based on a small number of poor-quality nonrandomised studies and these conclusions should be considered tentative.
Authors' objectives
To determine the effect of Helicobacter pylori (H. pylori) eradication therapy on platelet count response in patients with immune thrombocytopaenia purpura.
Searching
Published trials were identified through a search of MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL). Search dates were not reported. Abstracts from the American Society of Hematology were searched (2003 to 2007) . Experts were contacted for additional references and handsearching was undertaken. Search terms were reported. No language restrictions were applied. Two reviewers independently searched the databases.
Study selection
Studies that described platelet count response following H. Pylori eradication in patients with immune thrombocytopaenia purpura (ITP) were eligible for inclusion. Studies were required to report platelet counts for both infected and non-infected patients. Eradication therapy had to include at least one antibiotic and a proton pump inhibitor. Studies that reported only H. pylori-positive patients and case reports of fewer than five patients were excluded. Outcomes included platelet count response, bleeding and quality of life.
H. pylori was diagnosed using the urea breath test in all but one study. Treatment consisted of amoxicillin (200 to 400mg bid) and clarithromycin (200 to 400mg bid) and a proton pump inhibitor for seven days in all but one study. Platelet count values varied between studies (range ≤50x109/L to ≤120x109/L). Most patients (68%) were female. Average age was 51.6 ± 17.1 years. Eight of the 11 studies were conducted in Japan.
Two reviewers independently selected studies for inclusion. Disagreements were resolved by consensus.
Assessment of study quality
Methodological quality was assessed by two independent reviewers who derived four key study design features from two scales, MOOSE statement and a methodological index tool for non-randomised studies. Items included: prospective data collection; consecutive patients unselected for H. pylori infection status; duration of follow-up reported; and loss to follow-up reported. Disagreements were resolved by consensus.
Data extraction
Two independent reviewers used data on the number of events in each group (overall, partial and complete response) following eradication therapy to derive odds ratios (OR) and 95% confidence intervals (CI). Disagreements were resolved by consensus. Two definitions of overall response were used: definitions from the included studies; and a standard definition of a platelet count rise to at least 30x109/L within six months. Authors of included trials were contacted for any unpublished data.
Methods of synthesis
Pooled odds ratios and corresponding 95% CIs were calculated using a fixed-effect meta-analysis for overall response outcomes. A descriptive sensitivity analysis was conducted to test the influence of studies that enrolled consecutive patients whose infection status was not known until after the effect of treatment had been assessed. Publication bias was assessed using funnel plots.
